- Home
- IBRX vs VRE Comparison
IBRX vs VRE Comparison
Compare IBRX & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- VRE
- Stock Information
- Founded
- IBRX 2014
- VRE 1949
- Country
- IBRX United States
- VRE United States
- Employees
- IBRX N/A
- VRE N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- VRE Real Estate Investment Trusts
- Sector
- IBRX Health Care
- VRE Real Estate
- Exchange
- IBRX Nasdaq
- VRE Nasdaq
- Market Cap
- IBRX 1.9B
- VRE 1.6B
- IPO Year
- IBRX N/A
- VRE 1994
- Fundamental
- Price
- IBRX $2.94
- VRE $16.03
- Analyst Decision
- IBRX Strong Buy
- VRE Buy
- Analyst Count
- IBRX 3
- VRE 4
- Target Price
- IBRX $13.58
- VRE $18.25
- AVG Volume (30 Days)
- IBRX 6.3M
- VRE 458.9K
- Earning Date
- IBRX 11-12-2024
- VRE 02-19-2025
- Dividend Yield
- IBRX N/A
- VRE 1.64%
- EPS Growth
- IBRX N/A
- VRE N/A
- EPS
- IBRX N/A
- VRE N/A
- Revenue
- IBRX $7,332,000.00
- VRE $293,369,000.00
- Revenue This Year
- IBRX $2,515.60
- VRE N/A
- Revenue Next Year
- IBRX $766.19
- VRE $4.53
- P/E Ratio
- IBRX N/A
- VRE N/A
- Revenue Growth
- IBRX 1218.71
- VRE 11.63
- 52 Week Low
- IBRX $2.28
- VRE $13.84
- 52 Week High
- IBRX $10.53
- VRE $18.85
- Technical
- Relative Strength Index (RSI)
- IBRX 48.30
- VRE 39.85
- Support Level
- IBRX $2.28
- VRE $15.86
- Resistance Level
- IBRX $2.54
- VRE $16.48
- Average True Range (ATR)
- IBRX 0.25
- VRE 0.35
- MACD
- IBRX 0.10
- VRE 0.03
- Stochastic Oscillator
- IBRX 64.71
- VRE 52.94
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.